News & events

News & events

Filter by:
  • Management TeamNews

VarmX announces appointment of John Glasspool as CEO

Leadership team fully strengthened to drive next phase of development Leiden, The Netherlands, 12 november 2024 VarmX, a biotech company...

  • Management TeamNews

VarmX announces appointment of Martijn Negen as COO

Leiden, The Netherlands, 10 september 2024 VarmX, a biotech company focusing on the development of innovative approaches for the reversal...

  • News

VarmX appoints Dr. Jan Öhrström as CEO, and Dr. Alex Gold to Supervisory Board

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the appointment...
  • News

VarmX appoints Dr. Gerard Short as Chief Medical Officer

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the appointment...
  • Scientific publications

VMX-C001 is a Bypassing Agent for FXa-inhibiting DOACs and Displays a Favorable Pharmacokinetic and Pharmacodynamic Profile

Reversal of anticoagulation is important for safe usage of oral factor (F)Xa-inhibiting direct oral anticoagulants (FXa-DOACs).

...
  • News

VarmX raises € 32 million series B financing

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the completion...
  • News

VarmX raises € 12.5 million to develop VMX-COO1

VarmX, Leiden based biotech company focusing on the development of therapies in the field of hemostasis and thrombosis, today announced...
  • News

Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors

VarmX announces publication in Nature Communications of groundbreaking snake venom inspired approach to restore blood clotting in patients using anticoagulants...
  • Scientific publications

Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors

The absence of an adequate reversal strategy to prevent and stop potential life-threatening bleeding complications is a major drawback to...

  • News

VarmX raises seed capital for development of VMX-C001

VarmX, a Dutch, Leiden based biotech company focusing on the development of therapies in the field of hemostasis and thrombosis,...

VMX-C001: Transforming the treatment of bleeding in patients taking Factor Xa DOACs

Portfolio